MAPT and Alzheimer disease: Furthermore, it has been shown that associations between plasma p-tau217 and PET markers evolve over the course of the disease [5]: plasma p-tau217 is associated with amyloid-PET in the earliest stages of AD, when tau burden is restricted to the medial temporal lobe.